SRDAN VERSTOVSEK to Immunotherapy
This is a "connection" page, showing publications SRDAN VERSTOVSEK has written about Immunotherapy.
Connection Strength
0.678
-
Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms. Hematol Oncol Clin North Am. 2021 04; 35(2):409-429.
Score: 0.284
-
The Rationale for Immunotherapy in Myeloproliferative Neoplasms. Curr Hematol Malig Rep. 2019 08; 14(4):310-327.
Score: 0.256
-
Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms. Hematol Oncol. 2018 Dec; 36(5):740-748.
Score: 0.060
-
Immunotherapy based approaches in myelofibrosis. Expert Rev Hematol. 2017 10; 10(10):903-914.
Score: 0.056
-
Protective specific immunity induced by cyclophosphamide plus tumor necrosis factor alpha combination treatment of EL4-lymphoma-bearing C57BL/6 mice. Cancer Immunol Immunother. 1995 Jun; 40(6):347-57.
Score: 0.012
-
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006 Apr 01; 106(7):1569-80.
Score: 0.006
-
Specific anti-EL4-lymphoma immunity in mice cured 2 years earlier with doxorubicin and interleukin-2. Cancer Immunol Immunother. 1996 May; 42(4):221-30.
Score: 0.003